Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SLC26A6 | Q9BXS9 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | ASPH | Q12797 | 2/20 | 0.41 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22609276 | 0.87 | ALDH1A1 (0.53) | ALDH1A1HTTKMT2AATMSLC26A6 | |
| SCHEMBL22609257 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HTTP4HTMKMT2APOLB | |
| SCHEMBL22609283 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HTTP4HTMKMT2APOLB | |
| SCHEMBL23453702 | 0.78 | VNN1 (0.46) | HTTKMT2APOLBSMN1; SMN2ASPH | |
| SCHEMBL23453720 | 0.76 | GRIA1 (0.48) | ALDH1A1HTT | |
| SCHEMBL22609239 | 0.76 | P4HTM (0.46) | P4HTMKMT2APPARAASPHKDM8 | |
| SCHEMBL20511088 | 0.75 | GAA (0.49) | ALDH1A1KMT2APOLB | |
| SCHEMBL22609213 | 0.73 | ALDH1A1 (0.38) | ALDH1A1HTTKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL23453709 | 0.71 | P4HTM (0.47) | HTTP4HTMKMT2APPARA | |
| SCHEMBL27627423 | 0.70 | LMNA (0.46) | ALDH1A1HTTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| EP-3731840-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | Orfan Biotech Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | PNPO, XDH, GLS | ALDH1A1 149/4885HTT 4735/4885P4HTM 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.